Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ING Groep NV — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while ING Groep NV trades at $31.94 (market cap $92.35B). The key difference: ING Groep NV is far larger — about 20.6× ACADIA Pharmaceuticals Inc.'s market cap, and ING Groep NV pays a 3.93% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ING | |
|---|---|---|
Market Cap | $4.49B | $92.35B |
Sector | Health | Financials |
52-Week High | $28.06 | $32.96 |
52-Week Low | $20.06 | $22.45 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ING trades at $32.24, up 0.44% today, with a bullish technical outlook supported by moving averages. The stock shows consistent earnings beats and a 27.84% net income margin. Recent news highlights strategic moves like a global subscription banking model and board appointments, reinforcing growth initiatives. Analyst consensus is strongly positive with 62.5% buy ratings.
The outlook remains favorable due to solid fundamentals and bullish sentiment, though risks include volatile cash flows and macroeconomic pressures. Upside potential is supported by a DCF intrinsic value of $34, suggesting modest appreciation from current levels. Investors should weigh strong profitability against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
